Get to Know This Progressively Degenerative Disease


The sooner Friedreich ataxia (FA) is confirmed with the right genetic test, the sooner you can guide your patients to optimal supportive care.3


FA is a multisystem disease, so it is critical to connect patients and their families to the multidisciplinary support they need.4


The modified Friedreich Ataxia Rating Scale (mFARS) is a clinically validated neurological assessment and provides a detailed evaluation of a patient’s status. The mFARS can provide a clear picture of the relentless progression of FA and its severe impact on patient function.5

Stay Connected

Sign up to receive the latest news and resources for FA.

I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Biogen for marketing, including targeted online marketing, as well as to help develop new products, services, and programs. I understand that Biogen will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Biogen. I understand that I may revoke this authorization and choose not to receive information from Biogen by mailing a letter to Biogen, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC, 27709, using the link provided in emails I receive from Biogen, clicking the “unsubscribe” link at the bottom of this page, or sending an email with the subject “Unsubscribe” to [email protected]. For more information visit

Residents of certain US States (including but not limited to California) may have additional rights regarding the collection, use, maintenance, disclosure, and deletion of your personal information. To understand or exercise those rights California residents please visit For more information, visit

References: 1. National Institute of Neurological Disorders and Stroke. Friedreich Ataxia Fact Sheet. November 15, 2021. Accessed March 16, 2022. 2. Schulz JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009;5(4):222-234. 3. Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol. 2007;6(3):245-257. 4. de Silva RN, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M. Diagnosis and management of progressive ataxia in adults. Pract Neurol. 2019;19(3):196-207. 5. Rummey C, Corben LA, Delatycki MB, et al. Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet. 2019;5(6):371.

You are now leaving

You are now leaving This link will take you to a website that is outside the control of Biogen. Links are provided as a courtesy for informational purposes only. We do not make or imply any endorsement of external websites.

Return to Continue

You are now leaving

You are about to leave contains links that are provided as a courtesy for informational purposes only. We do not make or imply any endorsement of external websites.

Return to Continue